跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 85 条关于
“CHK2”
全部
85
临床试验
21
药物
48
机构
0
资讯
16
去年
Acrivon Therapeutics to Showcase AP3 Platform and Clinical Program Updates at Upcoming R&D Event
去年
Acrivon Therapeutics Grants Equity Awards to Employees Under Nasdaq Rule 5635(c)(4)
7个月前
Acrivon Therapeutics Launches CLIA-Certified Laboratory to Advance Precision Medicine Development
去年
Acrivon Therapeutics Appoints Renowned Oncologist Dr. Mansoor Raza Mirza as Chief Medical Officer to Lead Clinical Development
5个月前
Gilead Exercises Option for Kymera's KT-200 CDK2 Degrader, Triggering $45M Milestone Payment
去年
Gilead and Kymera Partner on Novel CDK2 Molecular Glue Degrader for Cancer Treatment
去年
Evergreen Theragnostics Initiates Phase II Trial of 68Ga-EVG321 for Small Cell Lung Cancer in the EU
去年
Novel CDK2 Inhibitor INX-315 Shows Promise in Overcoming Cancer Drug Resistance, Study Reveals
9个月前
Avenzo's CDK2 Inhibitor AVZO-021 Shows Promising Activity in Breast and Ovarian Cancer Patients
4个月前
Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer
第 1 页,共 2 页
上一页
下一页